Evidence map›Paper›PMID 33203180›Full record

ReviewPlants (Basel, Switzerland)2020

Progress in the Chemistry of Macrocyclic Meroterpenoids.

Dmitriy N Shurpik, Alan A Akhmedov, Peter J Cragg, Vitaliy V Plemenkov, Ivan I Stoikov

Abstract readReview
In one paragraph

Review in Plants (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dmitriy N ShurpikA.M. Butlerov Chemical Institute, Kazan Federal University, 18 Kremlevskaya Street, Kazan 420008, Russia.ORCID 0000-0002-7914-6533
Alan A AkhmedovA.M. Butlerov Chemical Institute, Kazan Federal University, 18 Kremlevskaya Street, Kazan 420008, Russia.ORCID 0000-0001-7630-7525
Peter J CraggSchool of Pharmacy and Biomolecular Sciences, University of Brighton, Huxley Building, Moulsecoomb Brighton, East Sussex BN2 4GJ, UK.ORCID 0000-0002-6134-2093
Vitaliy V PlemenkovA.M. Butlerov Chemical Institute, Kazan Federal University, 18 Kremlevskaya Street, Kazan 420008, Russia.
Ivan I StoikovA.M. Butlerov Chemical Institute, Kazan Federal University, 18 Kremlevskaya Street, Kazan 420008, Russia.ORCID 0000-0002-3019-7866

Funding

Council on grants of the President of the Russian Federation NSh-2499.2020.3Russian Foundation for Basic Research 18-03-00315Russian Foundation for Basic Research 19-33-90170
6 · The paper itself

Abstract

In the last decade, the chemistry of meroterpenoids-conjugated molecules formed from isoprenyl fragments through biosynthetic pathways-has developed rapidly. The class includes some natural metabolites and fully synthetic fragments formed through nonbiological synthesis. In the field of synthetic receptors, a range of structures can be achieved by combining fragments of different classes of organic compounds into one hybrid macrocyclic platform which retains the properties of these fragments. This review discusses the successes in the synthesis and practical application of both natural and synthetic macrocycles. Among the natural macrocyclic meroterpenoids, special attention is paid to isoprenylated flavonoids and phenols, isoprenoid lipids, prenylated amino acids and alkaloids, and isoprenylpolyketides. Among the synthetic macrocyclic meroterpenoids obtained by combining the "classical" macrocyclic platforms, those based on cyclodextrins, together with meta- and paracyclophanes incorporating terpenoid fragments, and meroterpenoids obtained by macrocyclization of several terpene derivatives are considered. In addition, issues related to biomedical activity, processes of self-association and aggregation, and the formation of host-guest complexes of various classes of macrocyclic merotenoids are discussed in detail.

Indexed as

associationshost–guest systemsmacrocyclic systemsterpenoids

Identifiers

PMID33203180
PMCPMC7696033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.